Company Overview

Septerna, Inc. is a biotechnology company focused on the discovery and development of medicines targeting G protein-coupled receptors (GPCRs), a large class of membrane proteins involved in many physiological processes and historically considered one of the most important categories of drug targets in the pharmaceutical industry. The company operates within the biotechnology and pharmaceutical research sectors, with an emphasis on creating orally available small-molecule therapeutics for diseases with significant unmet medical needs. Septerna’s platform is designed to address historically difficult GPCR targets by using structure-based drug discovery, computational chemistry, and proprietary receptor stabilization technologies.

The company’s primary value drivers are its internal therapeutic pipeline and its discovery platform for GPCR-targeted medicines. Septerna has focused development efforts in areas including endocrinology, immunology, inflammation, and metabolic diseases. The company evolved from stealth operations backed by venture capital financing and strategic pharmaceutical partnerships before becoming publicly traded on Nasdaq under the ticker SEPN. Its positioning is differentiated by its focus on “native-like” GPCR conformations and broad applicability across receptor classes that have traditionally proven difficult for drug developers.

Business Operations

Septerna organizes its operations primarily around drug discovery and early-stage clinical development. Its core business activities include identifying GPCR targets, engineering stabilized receptor structures, conducting medicinal chemistry optimization, and advancing therapeutic candidates through preclinical and clinical evaluation. Revenue generation has historically come from collaboration agreements, licensing arrangements, and financing activities rather than commercial product sales, as the company remains in the clinical-stage biotechnology phase.

The company maintains proprietary capabilities across receptor biology, computational modeling, and chemistry platforms that support its internal programs and partnered research initiatives. Septerna has entered into strategic collaborations with pharmaceutical companies to accelerate development and expand the application of its platform technologies. Its operations are primarily based in the United States, with research and corporate activities centered in California, while partnership activities extend internationally through industry collaborations and scientific networks.

Strategic Position & Investments

Septerna’s strategic direction centers on building a pipeline of differentiated GPCR-targeted therapies while leveraging its discovery platform through selective partnerships. The company has invested heavily in structure-enabled drug discovery infrastructure, receptor engineering technologies, and computational approaches intended to improve the predictability and efficiency of GPCR drug development. Public disclosures and investor materials indicate that management prioritizes therapeutic areas where oral small-molecule drugs may offer advantages over injectable biologics or less selective therapies.

The company has also pursued external validation through strategic financing rounds and industry collaborations involving large pharmaceutical organizations. Septerna’s investments are concentrated in advancing clinical and preclinical candidates, expanding receptor target coverage, and strengthening translational research capabilities. Emerging areas of interest include endocrine disorders, inflammatory diseases, and metabolic conditions where GPCR modulation could provide novel therapeutic approaches. Data regarding any large-scale international subsidiaries or material portfolio holdings remains limited in available public filings.

Geographic Footprint

Septerna is headquartered in South San Francisco, California, within the broader United States biotechnology sector concentrated in the San Francisco Bay Area. The company’s operational footprint is primarily domestic, with research, development, and corporate activities conducted in the United States. Its geographic influence extends internationally through scientific collaborations, licensing relationships, and engagement with global pharmaceutical partners.

Although Septerna does not currently maintain the broad commercial infrastructure associated with multinational pharmaceutical companies, its research and partnership activities position it within the global biotechnology ecosystem. The company’s investor base, collaborative relationships, and participation in international scientific and pharmaceutical networks provide exposure to markets across North America, Europe, and other major biotechnology regions.

Leadership & Governance

Septerna’s leadership team combines experience in biotechnology research, pharmaceutical development, and corporate strategy. The company was founded by scientists and biotechnology entrepreneurs focused on advancing GPCR-targeted therapeutics through modern structural biology and drug discovery techniques. Management has emphasized disciplined pipeline development, scientific innovation, and partnership-driven growth as core elements of corporate strategy.

Key executives and leadership figures include:

• Jeffrey Finer, M.D., Ph.D. – Chief Executive Officer
• Keith Sheppard, Ph.D. – Co-Founder and Chief Scientific Officer
• Mark Bouzyk, Ph.D. – Chief Technology Officer
• Katherine Stueland – Chair of the Board
• David Goeddel, Ph.D. – Co-Founder and Board Member

The company’s governance structure reflects standard public biotechnology company practices, including oversight by a board with scientific, operational, and financial expertise. Leadership communications in public filings and investor presentations emphasize advancing a scalable GPCR discovery platform, disciplined capital allocation, and long-term pipeline development.